DOJ reportedly has ‘significant concerns’ about Aetna-Humana merger

John Gregory | | Health Exec | Economics

Reuters is reporting the U.S. Department of Justice (DOJ) has concerns about the antitrust implications of Aetna’s $34 billion proposed acquisition of Humana, according to an anonymous source within the department.

State insurance regulators in Missouri and California have asked the DOJ to block the deal for its “anticompetitive impact,” particularly based on the Medicare Advantage market share the combined insurer would control.

To read more about when and why the DOJ may get in the way of the proposed merger, click on the link below: 

Justice Dept. has concerns over Aetna-Humana deal: source

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

Cardiologist compensation still rising, especially in invasive and interventional cardiology
Baxter begins importing IV supplies as 86% of providers report shortages
CMS proposes rule to combat gray market health insurance scams
Private equity firm buys controlling stake in Surescripts
Orlando Health buys 5 Alabama hospitals for $910M
92% of rural Nebraska hospitals report financial hardship caused by Medicare Advantage plans

Around the web

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Cardiovascular Business
Cardiology groups cheer new bill that would improve access to Medicare claims data

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup